BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16712669)

  • 1. Effect of obesity and morbid obesity on the growth hormone (GH) secretion elicited by the combined GHRH + GHRP-6 test.
    Kelestimur F; Popovic V; Leal A; Van Dam PS; Torres E; Perez Mendez LF; Greenman Y; Koppeschaar HP; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):667-71. PubMed ID: 16712669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.
    Popovic V; Leal A; Micic D; Koppeschaar HP; Torres E; Paramo C; Obradovic S; Dieguez C; Casanueva FF
    Lancet; 2000 Sep; 356(9236):1137-42. PubMed ID: 11030292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
    Cordido F; Alvarez-Castro P; Isidro ML; Casanueva FF; Dieguez C
    Eur J Endocrinol; 2003 Aug; 149(2):117-22. PubMed ID: 12887288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men.
    Haijma SV; van Dam PS; de Vries WR; Maitimu-Smeele I; Dieguez C; Casanueva FF; Koppeschaar HP
    Eur J Endocrinol; 2005 Apr; 152(4):575-80. PubMed ID: 15817913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single growth hormone (GH) determination is sufficient for the diagnosis of GH-deficiency in adult patients using the growth hormone releasing hormone plus growth hormone releasing peptide-6 test.
    Leal A; Lage M; Popovic V; Torres E; Koppeschaar HP; Paramo C; Micic D; Garcia-Mayor RV; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):377-84. PubMed ID: 12201831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
    Cordido F; Peñalva A; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone response to GHRH, GHRP-6 and GHRH + GHRP-6 in patients with polycystic ovary syndrome.
    Micić D; Kendereski A; Popović V; Sumarac M; Zorić S; Macut D; Dieguez C; Casanueva F
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):385-90. PubMed ID: 8959075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY; Granda-Ayala R
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index.
    Corneli G; Di Somma C; Baldelli R; Rovere S; Gasco V; Croce CG; Grottoli S; Maccario M; Colao A; Lombardi G; Ghigo E; Camanni F; Aimaretti G
    Eur J Endocrinol; 2005 Aug; 153(2):257-64. PubMed ID: 16061832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical activity or food intake prior to testing did not affect the reproducibility of GH secretion elicited by GH releasing hormone plus GH-releasing hexapeptide in normal adult subjects.
    Popovic V; Pekic S; Simic M; Damjanovic S; Micic D; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):89-94. PubMed ID: 11849251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of arginine + GHRH test compared with GHRH + GHRP-6 test in diagnosing growth hormone deficiency in adults.
    Popovic V; Pekic S; Doknic M; Micic D; Damjanovic S; Zarkovic M; Aimaretti G; Corneli G; Ghigo E; Deiguez C; Casanueva FF
    Clin Endocrinol (Oxf); 2003 Aug; 59(2):251-7. PubMed ID: 12864804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus.
    Micić D; Macut D; Popović V; Kendereski A; Sumarac-Dumanović M; Zorić S; Dieguez C; Casanueva FF
    Metabolism; 1999 Apr; 48(4):525-30. PubMed ID: 10206449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P; Isidro L; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
    Alvarez-Castro P; Isidro ML; Garcia-Buela J; Leal-Cerro A; Broglio F; Tassone F; Ghigo E; Dieguez C; Casanueva FF; Cordido F
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
    Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test.
    Gasperi M; Aimaretti G; Scarcello G; Corneli G; Cosci C; Arvat E; Martino E; Ghigo E
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2633-7. PubMed ID: 10443652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.
    Pihoker C; Middleton R; Reynolds GA; Bowers CY; Badger TM
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2987-92. PubMed ID: 7559885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.